Michael J Fox Foundation adviser joins NRG Therapeutics

NRG Therapeutics expands team with CDO appoint

NRG Therapeutics appoints Paul Thompson as CDO

UK Life Sciences Future50 - Momrentum in an evolving landscape

11 neuroscience biotech companies you should know about

Is this mitochondria’s big moment?

Biotechs, BIA, patient charities and investors: the power of relationships

NRG Therapeutics: Restoring motor neuron function via mitochondria

NRG raises $67M to test mitochondrial pore inhibitor in ALS

A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria

UK’s NRG Powers Up With £50m For Promising Mitochondrial Therapy

NRG raises $67 million for a small molecule for Parkinson’s and ALS

Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson's and ALS

A British mitochondrial startup wants to break ground in ALS and Parkinson's. It has £50M to try

Mitochondria: Movers and Shakers - a podcast about life with Parkinson's

Novel Parkinson’s therapy protects mitochondrial function

NRG Therapeutics launches Series B after $5m boost from Michael J. Fox Foundation

NRG Therapeutics gets grant to test mitochondria-targeting ALS therapy

Case Study: Life Sciences - Future50

9 neuroscience biotech companies you should know about

MJFF grant supports NRG Therapeutics' work to validate mitochondrial drug target for Parkinson's

Case Study: R&D grant funding

Parkinson’s disease drug hunters think outside the α-synuclein box

NRG raises Series A funds for Parkinson’s and ALS therapy development

Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS

NRG announces £16m Series A for IND for Parkinson’s and ALS

Following the path to a new drug, together

NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson's, ALS

Omega Funds leads £16m Series A round for NRG Therapeutics

NRG closes £16M series A to fund fight against neurodegenerative diseases

GSK vets theorize that a mitochondrial target may unlock Parkinson's and ALS treatments in new startup

NRG Therapeutics and Domainex to collaborate on discovery of small molecules to treat Parkinson’s or motor neurone disease

NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment

NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders

NRG Therapeutics to develop small molecule disease-modifying medicines for debilitating chronic neurodegenerative disorders

£2.68M Award to NRG Therapeutics Supports Work Into Potential DMT

Award to help NRG Therapeutics develop new Parkinson’s and Motor Neurone Disease treatments

NRG receives £2.68m funding boost for neurodegenerative disorders

Sticking plaster for brain could beat Parkinson’s disease

NRG Therapeutics awarded £2.68m to fight Parkinson’s and MND

NRG gearing up for series A to advance brain-penetrant PTP inhibitors

Parkinson’s UK takes investment in NRG Therapeutics to £2.5m

Cambridge neuroscience specialist NRG Therapeutics secures $500,000 from The Michael J Fox Foundation for Parkinson’s Research

NRG Therapeutics wins $500K from Michael J. Fox Foundation for Parkinson’s programme